组织细胞肿瘤患者中断靶向治疗后的结局
本研究为经机构审查委员会批准的研究,纳入达到完全或部分代谢缓解后中断BRAF和MEK抑制剂的组织细胞肿瘤成人患者,17/22(77%)在中断后出现疾病复发;中断前达完全缓解、携带非BRAFV600E突变及仅接受MEK抑制剂治疗均与无复发生存改善相关。
要点
- 中断靶向治疗后17/22(77%)患者出现疾病复发。
- 中断前达完全缓解与非BRAFV600E突变及仅用MEK抑制剂各与无复发生存改善相关。
- 复发在中断治疗后常见,但部分患者可能适合有限疗程治疗。
核心结论
- 中断靶向治疗后复发常见,但部分患者可能适合有限疗程治疗。
研究设计与样本
- 经机构审查委员会批准的研究,纳入组织细胞肿瘤成人患者,在经18-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)评估达到完全或部分缓解后中断BRAF和MEK抑制剂。
主要发现
- 17/22(77%)患者在中断治疗后出现疾病复发。
- 中断前达完全缓解、携带非BRAFV600E突变及仅接受MEK抑制剂治疗各与无复发生存改善呈统计学显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Little is known about outcomes following interruption of targeted therapy in adult patients with histiocytic neoplasms. This is an IRB-approved study of patients with histiocytic neoplasms whose BRAF and MEK inhibitors were interrupted after achieving complete or partial response by 18-fluorodeoxyglucose positron emission tomography (FDG-PET). 17/22 (77%) of patients experienced disease relapse following treatment interruption. Achieving a complete response prior to interruption, having a mutation other than BRAFV600E, and receiving MEK inhibition only were each associated with a statistically significant improvement in relapse-free survival. Relapse is common following treatment interruption however some patients may be suitable for limited-duration treatment.
引用
- Reiner AS, Durham BH, Yabe M, et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol. 2023. PMID: 37400251. doi:10.1111/bjh.18964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。